Gossamer Bio, Inc.
Public company- Headquarters
- SAN DIEGO, California
- Ticker
- GOSS
- CIK
- 0001728117
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| Class III directorGregory A. Ciongoli | Sep 16, 2026 | Appointed |
Related companies
Same industry and state, with recent events.
- ACADIA PHARMACEUTICALS INC
Executive Vice President, Head of Research and Development departs: Elizabeth H.Z. Thompson, Ph.D.
- KYNTRA BIO, INC.
Class III director appointed: Andrew E. Singer, MBA
- BIOMARIN PHARMACEUTICAL INC
WARN notice: Novato, CA
- CORCEPT THERAPEUTICS INC
President of Corcept Endocrinology departs: Sean Maduck
- Executive appointment
Class III director appointed: Gregory A. Ciongoli
Gregory A. Ciongoli was named Class III director of Gossamer Bio, Inc., effective September 16, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Sep 16, 2026Role: Class III director
layoffs from May 15, 2026
WARN noticeWARN notice: CA
Gossamer Bio, Inc. filed a WARN notice with the California WARN list on Mar 16, 2026 covering 65 workers. The layoffs take effect on May 15, 2026.
Source: California WARN list, filed Mar 16, 2026Site: CA
Workers affected: 65
Last verified Nov 8, 2026